Home Stock

Stock Research: BioLife Slutn

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

BioLife Slutn

NAQ:BLFS US09062W2044
74
  • Value
    5
  • Growth
    47
  • Safety
    Safety
    29
  • Combined
    34
  • Sentiment
    37
  • 360° View
    360° View
    74
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

BioLife Solutions, Inc. develops and supplies cell processing tools and services for the cell and gene therapy (CGT) market. The company operates in the cell and gene therapy market, offering solutions for cell preservation and processing. Its products include CryoStor freeze media, Sexton cell processing product line, CellSeal cryogenic vials, and ThawSTAR thawing devices. In the last fiscal year, the company had a market cap of $1,000 million, profits of $54 million, and revenue of $82 million with 159 employees.

more

ANALYSIS: With an Obermatt 360° View of 74 (better than 74% compared with alternatives), overall professional sentiment and financial characteristics for the stock BioLife Slutn are above average. The 360° View is based on consolidating four consolidated indicators, with all four indicators below average for BioLife Slutn. The consolidated Value Rank has a low rank of 5 which means that the share price of BioLife Slutn is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 95% of alternative stocks in the same industry. The consolidated Growth Rank also has a low rank of 47, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is lower than for 47% of competitors in the same industry. The consolidated Safety Rank has a riskier rank of 29, which means that the company has a riskier financing structure than 71% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a low rank of 37, which means that professional investors are more pessimistic about the stock than for 63% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Market Pulse
Country USA
Industry Life Sciences Tools & Services
Size Small
Website biolifesolutions.com
Index
NASDAQ
BioLife Slutn stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Aug-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
5 20 44 63
Growth
47 91 27 71
Safety
Safety
29 20 56 56
Sentiment
37 82 33 17
360° View
360° View
74 71 81 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
13 84 61 23
Opinions Change
5 50 50 50
Pro Holdings
n/a 63 32 75
Market Pulse
97 40 36 16
Sentiment
37 82 33 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
5 20 44 63
Growth
47 91 27 71
Safety Safety
29 20 56 56
Combined
34 33 72 72
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
9 11 38 62
Price vs. Earnings (P/E)
3 58 58 6
Price vs. Book (P/B)
45 40 58 79
Dividend Yield
1 1 1 1
Value
5 20 44 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
84 4 10 71
Profit Growth
50 90 90 9
Capital Growth
4 95 9 91
Stock Returns
69 87 47 53
Growth
47 91 27 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
95 60 53 62
Refinancing
36 18 39 31
Liquidity
6 14 28 28
Safety Safety
29 20 56 56

Similar Stocks

Discover high‑ranked alternatives to BioLife Slutn and broaden your portfolio horizons.

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Merck (USA)

NYQ:MRK
Country: USA
Industry: Pharmaceuticals
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews